Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2022-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for NKMAX Co., Ltd. covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business operations, capital structure, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from NKMAX regarding the adjustment of the conversion price for convertible bonds (13th series) due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like convertible bonds, falls under the 'Capital/Financing Update' category as it directly relates to financing activities and the terms of debt-to-equity conversion.
2022-10-17 Korean
투자판단관련주요경영사항(HER2 양성의 국소적으로 진행된 절제불가능 또는 전이성 위암 환자를 대상으로 트라스투주맙/XP와 병용 투여하는 SNK02의 안전성과 잠재적 유효성을 평가하기 위한 단일기관, 공개, 제1/2a상 임상시험 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (NKMAX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for a Phase 1/2a clinical trial for a new drug (SNK02). This type of disclosure is a standard regulatory requirement for publicly traded companies to inform shareholders of significant operational developments. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the 'Regulatory Filings' (RNS) category.
2022-08-22 Korean
불성실공시법인미지정(지정유예)
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement from the KOSDAQ market regarding the status of a company (NKMAX) as a 'non-designated' entity for unfair disclosure practices. It details the regulatory decision, the grounds for the decision (KOSDAQ disclosure regulations), and the specific history of disclosure delays. Since this is a formal regulatory notice regarding compliance and disclosure status that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-08-19 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for NKMAX Co., Ltd. for the period ending June 30, 2022. It contains comprehensive financial information, business descriptions, capital structure, and management details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
불성실공시법인지정예고(공시불이행 2건)
Regulatory Filings Classification · 100% confidence The document is a formal notice from a regulatory body (KOSDAQ) regarding the 'designation of an unfaithful disclosure corporation' (불성실공시법인지정예고) due to delayed disclosures. This is a regulatory notification concerning compliance and potential penalties, which falls under the category of regulatory filings or legal/regulatory notices. Since it does not fit into specific categories like M&A, dividends, or financial reports, it is best classified as a Regulatory Filing (RNS).
2022-07-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.